Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT01435616
Registration number
NCT01435616
Ethics application status
Date submitted
9/09/2011
Date registered
16/09/2011
Date last updated
13/04/2018
Titles & IDs
Public title
A Study in Patients With Type 2 Diabetes Mellitus
Query!
Scientific title
A Comparison of LY2605541 Versus Insulin Glargine as Basal Insulin Treatment in Combination With Oral Anti-Hyperglycemia Medications in Insulin-Naive Patients With Type 2 Diabetes Mellitus: A Double-Blind, Randomized Study
Query!
Secondary ID [1]
0
0
I2R-MC-BIAJ
Query!
Secondary ID [2]
0
0
12141
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
IMAGINE 2
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Diabetes Mellitus, Type 2
0
0
Query!
Condition category
Condition code
Metabolic and Endocrine
0
0
0
0
Query!
Diabetes
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Experimental: LY2605541 - LY2605541 titrated based on blood glucose readings, administered subcutaneously (SC), once daily in combination with at least 2 pre-study oral antihyperglycemic medications (OAMs) prescribed by the personal physician, for 52 or 78 weeks
Active comparator: Glargine - Glargine titrated based on blood glucose readings, administered SC, once daily in combination with at least 2 pre-study OAMs prescribed by the personal physician, for 52 or 78 weeks
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Change From Baseline to 52 Week Endpoint in Hemoglobin A1c (HbA1c)
Query!
Assessment method [1]
0
0
HbA1C is a test that measures a person's average blood glucose level over the past 2 to 3 months. Least Squares (LS) means were calculated using a mixed model repeated measures (MMRM) with baseline HbA1c measurement, stratification factors (country, low density lipoprotein-cholesterol \[LDL-C, \< 100 milligrams per deciliter {mg/dL} and = 100 mg/dL\] and sulfonylurea \[SU\]/meglitinide use), visit, treatment, and visit-by-treatment interaction as fixed effects.
Query!
Timepoint [1]
0
0
Baseline, 52 weeks
Query!
Secondary outcome [1]
0
0
Rate of Total and Nocturnal Hypoglycemia Events
Query!
Assessment method [1]
0
0
Hypoglycemia is a condition that occurs when a person's blood glucose level is lower than the normal range (less than or equal to 70 milligrams per deciliter \[mg/dL\] or less than 3.9 millimoles per liter \[mmol/L\]). Total hypoglycemia refers to an event that meets the criteria for documented symptomatic hypoglycemia, asymptomatic hypoglycemia, probable symptomatic hypoglycemia, unspecified hypoglycemia, or severe hypoglycemia. Nocturnal hypoglycemia refers to any total hypoglycemic event that occurs between bedtime and waking. Group mean (listed as LS means below) rates of total and nocturnal hypoglycemia were calculated using a negative binomial regression model (number of episodes = treatment + SU/meglitinide use + baseline hypoglycemia event rate, with log \[exposure per 30 days\] as the offset variable in the model).
Query!
Timepoint [1]
0
0
Baseline to 52 weeks
Query!
Secondary outcome [2]
0
0
Percentage of Participants With Hemoglobin A1c Equal or Less Than 6.5% and Less Than 7.0 %
Query!
Assessment method [2]
0
0
The percentage of participants was calculated by dividing the number of participants reaching target HbA1c by the total number of participants analyzed, multiplied by 100.
Query!
Timepoint [2]
0
0
52 weeks
Query!
Secondary outcome [3]
0
0
Fasting Serum Glucose (By Laboratory Measurement)
Query!
Assessment method [3]
0
0
LS means were calculated using a MMRM with baseline fasting serum glucose measurement, stratification factors (country, HbA1c, LDL-C \[\< 100 mg/dL and = 100 mg/dL\], and SU/meglitinide use), treatment, visit, and treatment-by-visit interaction as fixed effects.
Query!
Timepoint [3]
0
0
52 weeks
Query!
Secondary outcome [4]
0
0
Fasting Blood Glucose (By Participant Self-monitored Blood Glucose Readings)
Query!
Assessment method [4]
0
0
LS means were calculated using a MMRM with baseline fasting blood glucose measurement, stratification factors (country, HbA1c, LDL-C \[\< 100 mg/dL and = 100 mg/dL\], and SU/meglitinide use), treatment, visit, and treatment-by-visit interaction as fixed effects.
Query!
Timepoint [4]
0
0
52 weeks
Query!
Secondary outcome [5]
0
0
6 Point Self-monitored Blood Glucose (SMBG)
Query!
Assessment method [5]
0
0
Six-point SMBG profiles were obtained at pre-morning meal (fasting), pre-midday meal (lunch), pre-evening meal (dinner), bedtime, approximately 0300 hours, and pre-morning meal (fasting) the next day. Six-point SMBG profiles were obtained over 2 nonconsecutive days within the week prior to the next office visit. LS means were calculated using a MMRM with baseline blood glucose measurement, stratification factors (country, HbA1c, LDL-C \[\< 100 mg/dL and = 100 mg/dL\], and SU/meglitinide use), treatment, visit, and treatment-by-visit interaction as fixed effects.
Query!
Timepoint [5]
0
0
52 weeks
Query!
Secondary outcome [6]
0
0
Change From Baseline to 52 Weeks in Body Weight
Query!
Assessment method [6]
0
0
LS means were calculated using a MMRM with baseline body weight measurement, stratification factors (country, HbA1c, LDL-C \[\< 100 mg/dL and = 100 mg/dL\], and SU/meglitinide use), treatment, visit, and treatment-by-visit interaction as fixed effects.
Query!
Timepoint [6]
0
0
Baseline, 52 weeks
Query!
Secondary outcome [7]
0
0
Hemoglobin A1c
Query!
Assessment method [7]
0
0
HbA1c is a test that measures a person's average blood glucose level over the past 2 to 3 months. LS means were calculated using a MMRM with baseline HbA1C measurement, stratification factors (country, HbA1c, LDL-C \[\< 100 mg/dL and = 100 mg/dL\], and SU/meglitinide use), treatment, visit, and treatment-by-visit interaction as fixed effects.
Query!
Timepoint [7]
0
0
52 weeks
Query!
Secondary outcome [8]
0
0
Insulin Dose Per Body Weight
Query!
Assessment method [8]
0
0
LS means were calculated using a MMRM with baseline insulin dose measurement, stratification factors (country, HbA1c, LDL-C \[\< 100 mg/dL and = 100 mg/dL\], and SU/meglitinide use), treatment, visit, and treatment-by-visit interaction as fixed effects.
Query!
Timepoint [8]
0
0
52 weeks
Query!
Secondary outcome [9]
0
0
Number of Insulin Dose Adjustments to Steady-State
Query!
Assessment method [9]
0
0
Insulin doses were adjusted according to an algorithm (adapted from Riddle et al. 2003) during the first 26 weeks of the study and thereafter according to investigator judgment. Steady-state was defined as the first local maximum dose (maximum of moving 4-week interval) of LY2605541 or glargine within the window of +/- 2 weeks. The number of dose adjustments to steady-state was the total number of dose changes until steady-state was reached. LS means were calculated using a MMRM with baseline insulin dose measurement, stratification factors (country, HbA1c, LDL-C \[\< 100 mg/dL and = 100 mg/dL\], and SU/meglitinide use), treatment, visit, and treatment-by-visit interaction as fixed effects.
Query!
Timepoint [9]
0
0
Baseline to 52 weeks
Query!
Secondary outcome [10]
0
0
European Quality of Life-5 Dimension (EQ-5D)
Query!
Assessment method [10]
0
0
The EQ-5D is a generic, multidimensional, health-related, quality-of-life instrument. The profile allows participants to rate their health state in 5 health domains (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) using a 3-level scale of 1 to 3 (no problem, some problems, and extreme problems). These combinations of attributes are converted into a weighted health-state Index Score according to the United States population-based algorithm. Scores range from -0.11 to 1.0, where a score of 1.0 indicates perfect health. LS means were calculated using a MMRM with baseline stratification factors (country, HbA1c, and SU/meglitinide use), treatment, visit, and treatment-by-visit interaction as fixed effects.
Query!
Timepoint [10]
0
0
52 weeks
Query!
Secondary outcome [11]
0
0
Insulin Treatment Satisfaction Questionnaire
Query!
Assessment method [11]
0
0
The Insulin Treatment Satisfaction Questionnaire (ITSQ) is a validated instrument containing 22 items that assess treatment satisfaction for participants with diabetes who are receiving insulin. The questionnaire measures satisfaction from the following 5 domains: inconvenience of regimen, lifestyle flexibility, glycemic control, hypoglycemic control, and insulin delivery device. Data presented are the transformed total score on a scale of 0 to 100, where higher scores indicate better treatment satisfaction. LS means were calculated using a MMRM with stratification factors (country, HbA1c, and SU/meglitinide use), treatment, visit, and treatment-by-visit interaction as fixed effects.
Query!
Timepoint [11]
0
0
Up to 52 weeks
Query!
Secondary outcome [12]
0
0
Adult Low Blood Sugar Survey
Query!
Assessment method [12]
0
0
The adult Low Blood Sugar Survey (LBSS) is a validated, participant-reported 33-item questionnaire with items rated on a 5-point Likert scale, where 0 = never and 4 = always. The LBSS measures behaviors to avoid hypoglycemia and its negative consequences (15 items) and worries about hypoglycemia and its negative consequences (18 items). Total score is the sum of all items (range of 0 to 132). Higher total scores reflect greater fear of hypoglycemia. LS means were calculated using an analysis of covariance model (ANCOVA) with baseline LBSS score, stratification factors (country, HbA1c, and SU/meglitinide use), and treatment as fixed effects.
Query!
Timepoint [12]
0
0
Up to 52 weeks
Query!
Secondary outcome [13]
0
0
Change From Baseline to 52 Weeks in Triglycerides, Low Density Lipoprotein Cholesterol (LDL-C), and High Density Lipoprotein Cholesterol (HDL-C)
Query!
Assessment method [13]
0
0
LS means were calculated using a MMRM with baseline lipid measurement, stratification factors (country, HbA1c, LDL-C \[\< 100 mg/dL and = 100 mg/dL\], and SU/meglitinide use), treatment, visit, and treatment-by-visit interaction as fixed effects.
Query!
Timepoint [13]
0
0
Baseline, 52 weeks
Query!
Secondary outcome [14]
0
0
Percentage of Participants With Equal or Above 2-, and 3-fold Upper Limits of Normal (ULN) for Total Bilirubin
Query!
Assessment method [14]
0
0
Query!
Timepoint [14]
0
0
Up to 52 weeks
Query!
Secondary outcome [15]
0
0
Overall Treatment-Emergent Anti-LY2065541 Antibody Response (TEAR)
Query!
Assessment method [15]
0
0
The percentage of participants with a TEAR is summarized. TEAR is defined as a change in the anti-LY2605541 antibody level from undetectable at baseline to detectable at baseline, or, for those participants with detectable antibodies at baseline, change to a value with at least a 130% relative increase from baseline. Overall TEAR is defined as one or more TEAR during the specified period.
Query!
Timepoint [15]
0
0
Baseline to 78 weeks
Query!
Secondary outcome [16]
0
0
Intra-participant Variability of the Fasting Blood Glucose (FBG)
Query!
Assessment method [16]
0
0
Intra-participant variability of FBG, which was measured by SMBG, was assessed by the standard deviation of the FBG measurement at the Week 52 visit. LS means were calculated using a MMRM with baseline fasting blood glucose measurement, stratification factors (country, HbA1c, LDL-C \[\< 100 mg/dL and = 100 mg/dL\], and SU/meglitinide use), treatment, visit, and treatment-by-visit interaction as fixed effects.
Query!
Timepoint [16]
0
0
52 weeks
Query!
Secondary outcome [17]
0
0
Percentage of Participants With Total and Nocturnal Hypoglycemic Events
Query!
Assessment method [17]
0
0
A hypoglycemic event is defined by a blood glucose value =70 mg/dL (3.9mmol/L). Total hypoglycemic events include documented symptomatic hypoglycemia, asymptomatic hypoglycemia, probable symptomatic hypoglycemia, unspecified hypoglycemia, or severe hypoglycemia. Nocturnal hypoglycemic events refer to any total hypoglycemic event that occurs between bedtime and waking. The percentage of participants was calculated by dividing the number of participants with hypoglycemic or nocturnal hypoglycemic events by the total number of participants analyzed, multiplied by 100.
Query!
Timepoint [17]
0
0
Baseline to 52 weeks
Query!
Secondary outcome [18]
0
0
Percentage of Participants With HbA1C Equal or Less Than 6.5% and Less Than 7.0 % and Without Nocturnal Hypoglycemia
Query!
Assessment method [18]
0
0
The percentage of participants with HbA1C = 6.5% or \< 7.0% without nocturnal hypoglycemia is presented. Percentage was calculated by dividing the number of participants with the indicated HbA1c values over the total number of participants and multiplying by 100.
Query!
Timepoint [18]
0
0
Up to 52 weeks
Query!
Secondary outcome [19]
0
0
Percentage of Participants With Equal or Above 2- and 3-fold ULN for Alanine Transaminase/Serum Glutamic Pyruvic Transaminase (ALT/SGPT) and Aspartate Transaminase/Serum Glutamic Oxaloacetic Transaminase (AST/SGOT)
Query!
Assessment method [19]
0
0
The percentage of participants was calculated by dividing the number of participants equal or above 2- or 3-fold ULN for ALT/SGPT or AST/SGOT by the total number of participants analyzed, multiplied by 100.
Query!
Timepoint [19]
0
0
Up to 52 weeks
Query!
Eligibility
Key inclusion criteria
* Have type 2 diabetes mellitus, not treated with insulin, for at least 1 year prior to the study
* Have been receiving at least 2 OAMs for at least 3 months before entering the study
* Have a hemoglobin A1c (HbA1c) value between 7.0% and 11.0%, inclusive, at screening
* Are capable of and willing to inject insulin with a vial and syringe and perform self blood glucose monitoring
* Women of childbearing potential only: are not breastfeeding, have a negative pregnancy test at the time of screening and randomization, intend to not become pregnant during the trial, have practiced a reliable method of birth control for at least 6 weeks prior to screening, and agree to use a reliable method of birth control during the study and until 2 weeks following the last dose of study drug
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Have used insulin therapy (outside of pregnancy) anytime in the past 2 years, except for short-term treatment of acute conditions, and up to a maximum of 4 continuous weeks
* Use of rosiglitazone, pramlintide, or glucagon-like peptide 1 (GLP-1) receptor agonist (for example, exenatide, exenatide once weekly, or liraglutide) concurrently or within 3 months prior to screening
* Are currently taking, or have taken within the 3 months preceding screening, medications to promote weight loss
* Have had any episodes of severe hypoglycemia within 6 months prior to screening
* Have had 1 or more episodes of ketoacidosis or hyperosmolar state/coma in the 6 months prior to the study
* Have cardiac disease with functional status that is New York Heart Association Class III or IV (per New York Heart Association [NYHA] Cardiac Disease Classification)
* Have a history of renal transplantation, or are currently receiving renal dialysis or have serum creatinine greater or equal than 2 milligrams per deciliter (mg/dL)
* Have obvious clinical signs or symptoms of liver disease (excluding non- alcoholic fatty liver disease [NAFLD]), acute or chronic hepatitis, non-alcoholic steatohepatitis (NASH), or elevated liver enzyme measurements at screening
* Have had a blood transfusion or severe blood loss within 3 months prior to screening or have known hemoglobinopathy, hemolytic anemia or sickle cell anemia, or any other traits of hemoglobin abnormalities known to interfere with the measurement of HbA1c
* Have active or untreated malignancy or have been in remission from clinically significant malignancy for less than 5 years
* Have fasting or non-fasting triglycerides greater than 400 mg/dL (greater than 4.5 millimoles per liter [mmol/L]) at screening
* Are using lipid-lowering medication at a dose that has not been stable for 90 days prior to screening
* Are using niacin preparations as a lipid lowering medication and bile acid sequestrants within 90 days prior to screening
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/11/2011
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/01/2014
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
1538
Query!
Recruitment in Australia
Recruitment state(s)
NSW,SA,VIC,WA
Query!
Recruitment hospital [1]
0
0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Merewether
Query!
Recruitment hospital [2]
0
0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Keswick
Query!
Recruitment hospital [3]
0
0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Box Hill
Query!
Recruitment hospital [4]
0
0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Fremantle
Query!
Recruitment postcode(s) [1]
0
0
2291 - Merewether
Query!
Recruitment postcode(s) [2]
0
0
5035 - Keswick
Query!
Recruitment postcode(s) [3]
0
0
3128 - Box Hill
Query!
Recruitment postcode(s) [4]
0
0
6160 - Fremantle
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arizona
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
California
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Colorado
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Florida
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Georgia
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Hawaii
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Idaho
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Illinois
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Iowa
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Kansas
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Louisiana
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Maine
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Massachusetts
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Missouri
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Montana
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
New Hampshire
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
New Jersey
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Ohio
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Oregon
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Pennsylvania
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
South Carolina
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
Tennessee
Query!
Country [24]
0
0
United States of America
Query!
State/province [24]
0
0
Texas
Query!
Country [25]
0
0
United States of America
Query!
State/province [25]
0
0
Utah
Query!
Country [26]
0
0
United States of America
Query!
State/province [26]
0
0
Washington
Query!
Country [27]
0
0
Argentina
Query!
State/province [27]
0
0
Buenos Aires
Query!
Country [28]
0
0
Argentina
Query!
State/province [28]
0
0
Caba
Query!
Country [29]
0
0
Argentina
Query!
State/province [29]
0
0
Córdoba
Query!
Country [30]
0
0
Argentina
Query!
State/province [30]
0
0
Mar Del Plata
Query!
Country [31]
0
0
Brazil
Query!
State/province [31]
0
0
Marilia
Query!
Country [32]
0
0
Brazil
Query!
State/province [32]
0
0
Rio De Janeiro
Query!
Country [33]
0
0
Brazil
Query!
State/province [33]
0
0
Setor Oeste/Goiania
Query!
Country [34]
0
0
Brazil
Query!
State/province [34]
0
0
São Paulo
Query!
Country [35]
0
0
Canada
Query!
State/province [35]
0
0
Alberta
Query!
Country [36]
0
0
Canada
Query!
State/province [36]
0
0
British Columbia
Query!
Country [37]
0
0
Canada
Query!
State/province [37]
0
0
Manitoba
Query!
Country [38]
0
0
Canada
Query!
State/province [38]
0
0
Ontario
Query!
Country [39]
0
0
Canada
Query!
State/province [39]
0
0
Quebec
Query!
Country [40]
0
0
Finland
Query!
State/province [40]
0
0
Oulu
Query!
Country [41]
0
0
Finland
Query!
State/province [41]
0
0
Seinajoki
Query!
Country [42]
0
0
Germany
Query!
State/province [42]
0
0
Dippoldiswalde
Query!
Country [43]
0
0
Germany
Query!
State/province [43]
0
0
Dresden
Query!
Country [44]
0
0
Germany
Query!
State/province [44]
0
0
Friedrichsthal
Query!
Country [45]
0
0
Germany
Query!
State/province [45]
0
0
Furth Im Wald
Query!
Country [46]
0
0
Germany
Query!
State/province [46]
0
0
Goch
Query!
Country [47]
0
0
Germany
Query!
State/province [47]
0
0
Hamburg
Query!
Country [48]
0
0
Germany
Query!
State/province [48]
0
0
Ludwigshafen
Query!
Country [49]
0
0
Germany
Query!
State/province [49]
0
0
Münster
Query!
Country [50]
0
0
Germany
Query!
State/province [50]
0
0
Saarbrücken
Query!
Country [51]
0
0
Germany
Query!
State/province [51]
0
0
Schweinfurt
Query!
Country [52]
0
0
Germany
Query!
State/province [52]
0
0
Sulzbach
Query!
Country [53]
0
0
Greece
Query!
State/province [53]
0
0
Ampelokipoi
Query!
Country [54]
0
0
Greece
Query!
State/province [54]
0
0
Athens
Query!
Country [55]
0
0
Greece
Query!
State/province [55]
0
0
Thessaloniki
Query!
Country [56]
0
0
Hungary
Query!
State/province [56]
0
0
Budapest
Query!
Country [57]
0
0
Hungary
Query!
State/province [57]
0
0
Debrecen
Query!
Country [58]
0
0
Hungary
Query!
State/province [58]
0
0
Mako
Query!
Country [59]
0
0
Hungary
Query!
State/province [59]
0
0
Salgotarjan
Query!
Country [60]
0
0
Hungary
Query!
State/province [60]
0
0
Sopron
Query!
Country [61]
0
0
Israel
Query!
State/province [61]
0
0
Beer Sheva
Query!
Country [62]
0
0
Israel
Query!
State/province [62]
0
0
Haifa
Query!
Country [63]
0
0
Israel
Query!
State/province [63]
0
0
Raanana
Query!
Country [64]
0
0
Italy
Query!
State/province [64]
0
0
Carpi
Query!
Country [65]
0
0
Italy
Query!
State/province [65]
0
0
Castellanza
Query!
Country [66]
0
0
Italy
Query!
State/province [66]
0
0
Foggia
Query!
Country [67]
0
0
Italy
Query!
State/province [67]
0
0
Forli
Query!
Country [68]
0
0
Italy
Query!
State/province [68]
0
0
Rome
Query!
Country [69]
0
0
Italy
Query!
State/province [69]
0
0
Sesto San Giovanni
Query!
Country [70]
0
0
Lithuania
Query!
State/province [70]
0
0
Utena
Query!
Country [71]
0
0
Lithuania
Query!
State/province [71]
0
0
Vilnius
Query!
Country [72]
0
0
Mexico
Query!
State/province [72]
0
0
Coatzacoalcos
Query!
Country [73]
0
0
Mexico
Query!
State/province [73]
0
0
Mexico City
Query!
Country [74]
0
0
Mexico
Query!
State/province [74]
0
0
Monterrey
Query!
Country [75]
0
0
New Zealand
Query!
State/province [75]
0
0
Auckland
Query!
Country [76]
0
0
Poland
Query!
State/province [76]
0
0
Kamieniec Zabkowicki
Query!
Country [77]
0
0
Poland
Query!
State/province [77]
0
0
Katowice
Query!
Country [78]
0
0
Poland
Query!
State/province [78]
0
0
Krakow
Query!
Country [79]
0
0
Poland
Query!
State/province [79]
0
0
Lodz
Query!
Country [80]
0
0
Poland
Query!
State/province [80]
0
0
Ruda Slaska
Query!
Country [81]
0
0
Poland
Query!
State/province [81]
0
0
Szczecin
Query!
Country [82]
0
0
Poland
Query!
State/province [82]
0
0
Tychy
Query!
Country [83]
0
0
Poland
Query!
State/province [83]
0
0
Warsaw
Query!
Country [84]
0
0
Puerto Rico
Query!
State/province [84]
0
0
Hato Rey
Query!
Country [85]
0
0
Puerto Rico
Query!
State/province [85]
0
0
Manati
Query!
Country [86]
0
0
Puerto Rico
Query!
State/province [86]
0
0
San Juan
Query!
Country [87]
0
0
Romania
Query!
State/province [87]
0
0
Bucharest
Query!
Country [88]
0
0
Romania
Query!
State/province [88]
0
0
Cluj-Napoca
Query!
Country [89]
0
0
Romania
Query!
State/province [89]
0
0
Iasi
Query!
Country [90]
0
0
Romania
Query!
State/province [90]
0
0
Oradea
Query!
Country [91]
0
0
Romania
Query!
State/province [91]
0
0
Ploiesti
Query!
Country [92]
0
0
Romania
Query!
State/province [92]
0
0
Resita
Query!
Country [93]
0
0
Romania
Query!
State/province [93]
0
0
Targu-Mures
Query!
Country [94]
0
0
Russian Federation
Query!
State/province [94]
0
0
Cheboksary
Query!
Country [95]
0
0
Russian Federation
Query!
State/province [95]
0
0
Kazan
Query!
Country [96]
0
0
Russian Federation
Query!
State/province [96]
0
0
Kursk
Query!
Country [97]
0
0
Russian Federation
Query!
State/province [97]
0
0
Novosibirsk
Query!
Country [98]
0
0
Russian Federation
Query!
State/province [98]
0
0
Saint Petersburg
Query!
Country [99]
0
0
Slovakia
Query!
State/province [99]
0
0
Bratislava
Query!
Country [100]
0
0
Slovakia
Query!
State/province [100]
0
0
Sala
Query!
Country [101]
0
0
Slovakia
Query!
State/province [101]
0
0
Vranov Nad Toplou
Query!
Country [102]
0
0
South Africa
Query!
State/province [102]
0
0
Paarl
Query!
Country [103]
0
0
South Africa
Query!
State/province [103]
0
0
Parow
Query!
Country [104]
0
0
South Africa
Query!
State/province [104]
0
0
Somerset West
Query!
Country [105]
0
0
Spain
Query!
State/province [105]
0
0
Alicante
Query!
Country [106]
0
0
Spain
Query!
State/province [106]
0
0
Cordoba
Query!
Country [107]
0
0
Spain
Query!
State/province [107]
0
0
Pozuelo De Alarcon
Query!
Country [108]
0
0
Spain
Query!
State/province [108]
0
0
Requena
Query!
Country [109]
0
0
Spain
Query!
State/province [109]
0
0
Seville
Query!
Country [110]
0
0
Spain
Query!
State/province [110]
0
0
Toledo
Query!
Country [111]
0
0
Turkey
Query!
State/province [111]
0
0
Gaziantep
Query!
Country [112]
0
0
Turkey
Query!
State/province [112]
0
0
Hatay
Query!
Country [113]
0
0
Turkey
Query!
State/province [113]
0
0
Izmir
Query!
Country [114]
0
0
Turkey
Query!
State/province [114]
0
0
Kayseri
Query!
Country [115]
0
0
United Kingdom
Query!
State/province [115]
0
0
Berks
Query!
Country [116]
0
0
United Kingdom
Query!
State/province [116]
0
0
Leicestershire
Query!
Country [117]
0
0
United Kingdom
Query!
State/province [117]
0
0
Surrey
Query!
Country [118]
0
0
United Kingdom
Query!
State/province [118]
0
0
Wales
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Eli Lilly and Company
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is: * To compare blood sugar control on LY2605541 with insulin glargine after 52 weeks of treatment. * To compare the rate of night time low blood sugar episodes on LY2605541 with insulin glargine during 52 weeks of treatment. * To compare the number of participants on LY2605541 reaching blood sugar targets without low blood sugar episodes at night to those taking insulin glargine after 52 weeks of treatment. * To compare the rate of low blood sugar episodes on LY2605541 with insulin glargine after 52 weeks of treatment
Query!
Trial website
https://clinicaltrials.gov/study/NCT01435616
Query!
Trial related presentations / publications
Sanyal A, Cusi K, Hartman ML, Zhang S, Bastyr EJ 3rd, Bue-Valleskey JM, Chang AM, Haupt A, Jacober SJ, Konrad RJ, Zhang Q, Hoogwerf BJ. Cytokeratin-18 and enhanced liver fibrosis scores in type 1 and type 2 diabetes and effects of two different insulins. J Investig Med. 2018 Mar;66(3):661-668. doi: 10.1136/jim-2017-000609. Epub 2017 Nov 21. Orchard TJ, Cariou B, Connelly MA, Otvos JD, Zhang S, Antalis CJ, Ivanyi T, Hoogwerf BJ. The effects of basal insulin peglispro vs. insulin glargine on lipoprotein particles by NMR and liver fat content by MRI in patients with diabetes. Cardiovasc Diabetol. 2017 Jun 6;16(1):73. doi: 10.1186/s12933-017-0555-1. Cusi K, Sanyal AJ, Zhang S, Hartman ML, Bue-Valleskey JM, Hoogwerf BJ, Haupt A. Non-alcoholic fatty liver disease (NAFLD) prevalence and its metabolic associations in patients with type 1 diabetes and type 2 diabetes. Diabetes Obes Metab. 2017 Nov;19(11):1630-1634. doi: 10.1111/dom.12973. Epub 2017 Jun 22.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Query!
Address
0
0
Eli Lilly and Company
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results are available at
https://clinicaltrials.gov/study/NCT01435616
Download to PDF